2-Acetylpyridine Thiosemicarbazones
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1469
(42) Hu, W.-X.; Zhou, W.; Xia, C.-N.; Wen, X. Synthesis and anticancer
activity of thiosemicarbazones. Bioorg. Med. Chem. Lett. 2006, 16,
2213–2218.
(43) Kovala-Demertzi, D.; Yadav, P. N.; Wiecek, J.; Skoulika, S.; Vara-
dinova, T.; Demertzis, M. A. Zinc(II) complexes derived from
pyridine-2-carbaldehyde thiosemicarbazone and (1E)-1-pyridin-2-
ylethan-1-one thiosemicarbazone. Synthesis, crystal structures and
antiproliferative activity of zinc(II) complexes. J. Inorg. Biochem.
2006, 100, 1558–1567.
(44) Bisceglie, F.; Baldini, M.; Belicchi-Ferrari, M.; Buluggiu, E.; Careri,
M.; Pelosi, G.; Pinelli, S.; Tarasconi, P. Metal complexes of retinoid
derivatives with antiproliferative activity: synthesis, characterization
and DNA interaction studies. Eur. J. Med. Chem. 2007, 42, 627–634.
(45) Grguric-Sipka, S.; Kowol, C. R.; Valiahdi, S.-M.; Eichinger, R.;
Jakupec, M. A.; Roller, A.; Shova, S.; Arion, V. B.; Keppler, B. K.
Ruthenium(II) complexes of thiosemicarbazones: the first water-soluble
complex with pH dependent antiproliferative activity. Eur. J. Inorg.
Chem. 2007, 2870–2878.
(46) Matesanz, A. I.; Souza, P. Novel cyclopalladated and coordination
palladium and platinum complexes derived from R-diphenyl ethanedi-
one bis(thiosemicarbazones): Structural studies and cytotoxic activity
against human A2780 and A2780cisR carcinoma cell lines. J. Inorg.
Biochem. 2007, 101, 1354–1361.
terization, and antifungal activities of complexes of group 12 metals
with 2-acetylpyridine- and 2-acetylpyridine-N-oxide-4N-phenylthi-
osemicarbazones. Z. Anorg. Allg. Chem. 1999, 625, 961–968.
(60) Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion,
V. B.; Keppler, B. K. Effect of metal ion complexation and chalcogen
donor identity on the antiproliferative activity of 2-acetylpyridine N,N-
dimethyl(chalcogen)semicarbazones. J. Inorg. Biochem. 2007, 101,
1946–1957.
(61) West, D. X.; Scovill, J. P.; Silverton, J. V.; Bavoso, A. Nickel(II)
complexes of a thiosemicarbazone prepared from 2-acetylpyridine.
Transition Met. Chem. 1986, 11, 123–131.
(62) West, D. X.; Billeh, I. S.; Bain, G. A.; Valdes-Martinez, J.; Ebert,
K. H.; Hernandez-Ortega, S. Metal complexes of 2-acetylpyridine N(4)-
dihexyl- and N(4)-dicyclohexylthiosemicarbazones. Transition Met.
Chem. 1996, 21, 573–582.
(63) Nomiya, K.; Sekino, K.; Ishikawa, M.; Honda, A.; Yokoyama, M.;
Chikaraishi Kasuga, N.; Yokoyama, H.; Nakano, S.; Onodera, K.
Syntheses, crystal structures and antimicrobial activities of monomeric
8-coordinate, and dimeric and monomeric 7-coordinate bismuth(III)
complexes with tridentate and pentadentate thiosemicarbazones and
pentadentate semicarbazone ligands. J. Inorg. Biochem. 2004, 98, 601–
615.
(64) Usman, A.; Razak, I. A.; Chantrapromma, S.; Fun, H. K.; Philip, V.;
Sreekanth, A.; Prathapachandra Kurup, M. R. Di-2-pyridyl ketone
N4,N4-(butane-1,4-diyl)thiosemicarbazone. Acta Crystallogr., Sect. C:
Cryst. Struct. Commun. 2002, C58, o652-o654.
(65) Sreekanth, A.; Kurup, M. R. P. Synthesis, EPR and Mossbauer spectral
studies of new iron(III) complexes with 2-benzoylpyridine-N(4),N(4)-
(butane-1,4-diyl) thiosemicarbazone (HBpypTsc): X-ray structure of
[Fe(BpypTsc)2]FeCl4 ·2H2O and the free ligand. Polyhedron 2004, 23,
969–978.
(47) Dilovic, I.; Rubcic, M.; Vrdoljak, V.; Pavelic, S. K.; Kralj, M.;
Piantanida, I.; Cindric, M. Novel thiosemicarbazone derivatives as
potential antitumor agents: synthesis, physicochemical and structural
properties, DNA interactions and antiproliferative activity. Bioorg.
Med. Chem. 2008, 16, 5189–5198.
(48) Liu, M. C.; Lin, T. C.; Sartorelli, A. C. Synthesis and antitumor activity
of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.
J. Med. Chem. 1992, 35, 3672–3677.
(49) Cory, J. G.; Cory, A. H.; Rappa, G.; Lorico, A.; Liu, M.-C.; Lin, T.-
S.; Sartorelli, A. C. Inhibitors of ribonucleotide reductase: comparative
effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde
thiosemicarbazones. Biochem. Pharmacol. 1994, 48, 335–344.
(50) Feun, L.; Modiano, M.; Lee, K.; Mao, J.; Marini, A.; Savaraj, N.;
Plezia, P.; Almassian, B.; Colacino, E.; Fischer, J.; MacDonald, S.
Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxal-
dehyde thiosemicarbazone (3-AP) using a single intravenous dose
schedule. Cancer Chemother. Pharmacol. 2002, 50, 223–229.
(51) Wadler, S.; Makower, D.; Clairmont, C.; Lambert, P.; Fehn, K.; Sznol,
M. Phase I and pharmacokinetic study of the ribonucleotide reductase
inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, ad-
ministered by 96 h intravenous continuous infusion. J. Clin. Oncol.
2004, 22, 1553–1563.
(52) Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond,
G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxalde-
hyde thiosemicarbazone (3-AP) and gemcitabine in advanced pan-
creatic carcinoma. A trial of the Princess Margaret Hospital Phase II
consortium. InVest. New Drugs 2007, 25, 553–558.
(53) Attia, S.; Kolesar, J.; Mahoney, M. R.; Pitot, H. C.; Laheru, D.; Heun,
J.; Huang, W.; Eickhoff, J.; Erlichman, C.; Holen, K. D. A phase 2
consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemi-
carbazone (3-AP) for advanced adenocarcinoma of the pancreas. InVest.
New Drugs 2008, 26, 369–379.
(54) Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.;
Wang, L. Z.; Mo, F.; Chan, A. T. C.; Zee, B.; Mok, T. A. multicenter
phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
(3-AP, Triapine) and gemcitabine in advanced non-small-cell lung
cancer with pharmacokinetic evaluation using peripheral blood mono-
nuclear cells. InVest. New Drugs 2008, 26, 169–173.
(55) Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez,
K. M.; Cheng, Y.; Sartorelli, A. C. Triapine (3-aminopyridine-2-
carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucle-
otide reductase activity with broad spectrum antitumor activity.
Biochem. Pharmacol. 2000, 59, 983–991.
(56) Kumbhar, A.; Sonawane, P.; Padhye, S.; West, D. X.; Butcher, R. J.
Structure of antitumor agents 2-acetylpyridinethiosemicarbazone hemi-
hydrate and 2-acetylpyridinethiosemicarbazone hydrochloride. J. Chem.
Crystallogr. 1997, 27, 533–539.
(57) Bermejo, E.; Carballo, R.; Castineiras, A.; Dominguez, R.; Liberta,
A. E.; Maichle-Mossmer, C.; Salberg, M. M.; West, D. X. Synthesis,
structural characteristics, and biological activities of complexes of
Zn(II), Cd(II), Hg(II), Pd(II), and Pt(II) with 2-acetylpyridine-4-
methylthiosemicarbazone. Eur. J. Inorg. Chem. 1999, 96, 5–973.
(58) West, D. X.; Bain, G. A.; Butcher, R. J.; Valdes-Martinex, J.; Toscano,
R. A.; Hernandez-Ortega, S.; Jasinsky, J. P.; Li, Y.; Pozdniakiv, R. Y.
Structural studies of three isomeric forms of heterocyclic N(4)-
substituted thiosemicarbazones and two nickel(II) complexes. Poly-
hedron 1996, 15, 665–674.
(66) Ketcham, K. A.; Swearingen, J. K.; Castineiras, A.; Garcia, I.; Bermejo,
E.; West, D. X. Iron(III), cobalt(II, III), copper(II) and zinc(II)
complexes of 2-pyridineformamide 3-piperidylthiosemicarbazone.
Polyhedron 2001, 20, 3265–3273.
(67) Bermejo, E.; Castifieiras, A.; Fostiak, L. M.; Garcia, I.; Llamas-Saiz,
A. L.; Swearingen, J. K.; West, D. X. Synthesis; characterization and
molecular structure of 2-pyridylformamide N(4)-dimethylthiosemi-
carbazone and some five-coordinated zinc(II) and cadmium(II) com-
plexes. Z. Naturforsch., B: Chem. Sci. 2001, 56, 1297–1305.
(68) Richardson, D. R.; Bernhardt, P. V. Crystal and molecular structure
of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and
its iron(III) complex: an iron chelator with antitumor activity. J. Biol.
Inorg. Chem. 1999, 4, 266–273.
(69) Murphy, T. B.; Johnson, D. K.; Rose, N. J.; Aruffo, A.; Schomaker,
V. Structural studies of iron(III) complexes of the new iron-binding
drug, pyridoxal isonicotinoyl hydrazone. Inorg. Chim. Acta 1982, 66,
L67-L68.
(70) Avramovici-Grisaru, S.; Sarel, S.; Cohen, S.; Bauminger, R. E. The
synthesis, crystal and molecular-structure, and oxidation-state of iron
complex from pyridoxal isonicotinoyl hydrazone and ferrous sulfate.
Israel J. Chem. 1985, 25, 288–292.
(71) Bernhardt, P. V.; Wilson, G. J.; Sharpe, P. C.; Kalinowski, D. S.;
Richardson, D. R. Tuning the antiproliferative activity of biologically
active iron chelators: characterization of the coordination chemistry
and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine
hydrazone ligands. J. Biol. Inorg. Chem. 2008, 13, 107–119.
(72) Dunford, H. B. Oxidations of iron(II)/(III) by hydrogen peroxide: from
aquo to enzyme. Coord. Chem. ReV. 2002, 233-234, 311–318.
(73) Chaston, T. B.; Richardson, D. R. Redox chemistry and DNA
interactions of the 2-pyridyl-carboxaldehyde isonicotinoyl hydrazone
class of iron chelators: implications for toxicity in the treatment of
iron overload disease. J. Biol. Inorg. Chem. 2003, 8, 427–438.
(74) Chaston, T.; Lovejoy, D.; Watts, R. N.; Richardson, D. R. Examination
of the antiproliferative activity of iron chelators: multiple cellular
targets and the different mechanism of action of Triapine compared
to Desferrioxamine and the potent PIH analogue 311. Clin. Cancer
Res. 2003, 9, 402–414.
(75) Ledru, S.; Boujtita, M. Electrocatalytic oxidation of ascorbate by heme-
FeIII/heme-FeII redox couple of the HRP and its effect on the
electrochemical behavior of an L-lactate biosensor. Bioelectrochemistry
2004, 64, 71–78.
(76) Ponka, P.; Schulman, H. M. Acquisition of iron from transferrin
regulates reticulocyte heme synthesis. J. Biol. Chem. 1985, 260,
14717–14721.
(77) Ponka, P.; Schulman, H. M.; Wilczynska, A. Ferric pyridoxal
isonicotinoyl hydrazone can provide iron for heme synthesis in
reticulocytes. Biochim. Biophys. Acta 1982, 718, 151–156.
(78) Bernhardt, P. V.; Mattsson, J.; Richardson, D. R. Complexes of
cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone
(HPKIH) analogues. Inorg. Chem. 2006, 45, 752–760.
(59) Bermejo, E.; Castineiras, A.; Dominguez, R.; Carballo, R.; Maichle-
Mossmer, C.; Strahle, J.; West, D. X. Preparation, structural charac-